News headlines about Innoviva (NASDAQ:INVA) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.06872859509 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have effected Accern’s rankings:

INVA has been the topic of a number of recent analyst reports. Stifel Nicolaus restated a “neutral” rating on shares of Innoviva in a research report on Friday, September 15th. Zacks Investment Research upgraded shares of Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Wednesday, October 25th. Robert W. Baird restated a “hold” rating and set a $13.00 price target on shares of Innoviva in a research report on Tuesday, October 24th. Deutsche Bank initiated coverage on shares of Innoviva in a research report on Monday, November 20th. They set a “hold” rating and a $13.00 price target on the stock. Finally, Morgan Stanley restated an “underweight” rating and set a $8.00 price target (up from $7.00) on shares of Innoviva in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.50.

Shares of Innoviva (INVA) opened at $14.19 on Friday. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of -2.59. Innoviva has a fifty-two week low of $10.30 and a fifty-two week high of $14.87. The company has a market cap of $1,543.53, a P/E ratio of 16.31 and a beta of 2.52.

Innoviva (NASDAQ:INVA) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The business had revenue of $48.64 million during the quarter, compared to the consensus estimate of $57.18 million. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The firm’s revenue for the quarter was up 46.0% compared to the same quarter last year. analysts predict that Innoviva will post 1.08 earnings per share for the current fiscal year.

In related news, insider Michael W. Aguiar sold 12,022 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.13, for a total value of $157,848.86. Following the sale, the insider now directly owns 980,907 shares in the company, valued at approximately $12,879,308.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP George B. Abercrombie sold 5,215 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.26, for a total transaction of $69,150.90. Following the completion of the sale, the vice president now owns 263,866 shares in the company, valued at $3,498,863.16. The disclosure for this sale can be found here. Insiders sold a total of 32,522 shares of company stock worth $429,985 over the last quarter. Insiders own 1.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Insider Buying and Selling by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with's FREE daily email newsletter.